IMA Clinical Research Celebrates Top Honors at 2024 PharmaTimes Clinical Researcher Awards
IMA Clinical Research is proud to announce that two of its outstanding team members have been recognized at the PharmaTimes Clinical Researcher of the Year 2024 competition. Angel Goewey, Phoenix Site Director and Chelsea Jarvis, CCRC in Albuquerque, have secured gold and silver awards, respectively, in the Clinical Research Co-Ordinator (CRC) category.
Angel Goewey impressed the panel of industry experts with her innovative presentation, “AI Improving Participant Recruitment in CNS Trials.” Her work highlights how artificial intelligence can transform participant recruitment processes in central nervous system (CNS) trials, optimizing patient matching and engagement while reducing recruitment timelines.
Chelsea Jarvis received the silver award for her presentation on “TranslateAI,” which demonstrated the potential of AI-driven language solutions to improve communication and accessibility for diverse populations in clinical trials. Her insights into real-time language translation underscore the increasing role of technology in bridging language barriers in clinical research settings.
The PharmaTimes Clinical Researcher of the Year competition, now in its 14th year, is renowned for challenging clinical researchers in the pharmaceutical and clinical research sectors through rigorous assessment criteria. Finalists in 2024 were evaluated across a wide scope of roles and experience levels, providing a valuable platform for professional growth and feedback from industry mentors.
IMA Clinical Research extends heartfelt congratulations to Angel Goewey and Chelsea Jarvis for their exceptional achievements. Their dedication to pioneering innovative solutions exemplifies IMA’s commitment to excellence and advancing clinical research methodologies.
About IMA Clinical Research
IMA Clinical Research is a network of clinical research sites with over 150 satellite locations that provide extensive, nationwide patient access. With experienced investigators and clinicians, the network specializes in Phase II-IV, post-approval, site-based, hybrid, and fully decentralized trials across various therapeutic areas, including CNS, metabolic, vaccines, and more. IMA ensures efficient trial execution with centralized services for rapid startup—offering one budget, one contract, and streamlined regulatory submissions. The network emphasizes patient diversity, high retention, and quality care to advance the development of new medical treatments.